Biogelx announce Alison Clayton as new CEO

Biogelx, a Scottish biomaterials company is pleased to announce the appointment of Alison Clayton as their new Chief Executive Officer. Alison joins the company to succeed Mitch Scanlan who has recently retired after his tenure at Biogelx.

We are absolutely delighted to have Alison come on board here at Biogelx, her commercial experience coupled with her academic background will help move the company to the next phase of its evolution.”

John Waddell, Chairman

Alison joins Biogelx following over 25 years in the contract testing industry and has worked for companies such as Eurofins, Quintiles, and Aptuit.

She possesses a strong focus on operational and customer delivery. Alison has a degree and a Ph.D. from the University of Glasgow in Pharmacology and a strong background in academic research having spent 7 years in various post-doctoral research positions.

Alison Clayton

“I am excited to be joining Biogelx at this time when the applications for the products in 3D Bioprinting and also 3D Cell Culture are growing.” Said Alison Clayton, CEO “We have extensive collaborations ongoing with both academia and commercial organizations which further develop the applications for the products maximizing their utility within the research and development space.”

Margaret Temple has been appointed to the board of directors as a non-executive director. Margaret joined the Life Science industry in 1995 in business Development with Q-One Biotech Ltd.

She has over 25 years of global commercial management experience in the life science CRO sector. In 2007 she co-founded Vitrology Ltd and served as CEO from 2008 through to its acquisition by the Swiss multinational SGS in 2012.

Biogelx is excited to announce that they have completed a successful round of fundraising and would like to thank The University of Strathclyde, the Scottish Investment Bank, and their private investors.

This new round of investment will be used to support the growth and development of the business and research and development of new hydrogel and bioink products for use in 3D cell culture and 3D bioprinting.

About the Companies

Biogelx was formed as a spin-out company from Professor Rein Ulijn’s lab at the University of Strathclyde’s Department of Pure & Applied Chemistry. Professor Ulijn remains with Biogelx as CSO.

Biogelx core technology is self-assembling synthetic peptide products which have gained a global reputation in 3D cell culture for both Drug Discovery and Regenerative Medicine.

This core technology was also used to develop a product family of novel bioinks which allow for the development of advanced three-dimensional tissue models.

The University of Strathclyde is a leading technological university based in Glasgow with over 23,000 students from over 100 countries. Awarded the University of the Year 2019 in the Times Higher Education Awards being the first university to ever win the award twice,  and the Scottish University of the Year by the Sunday Times Good University Guide

The Scottish Investment Bank is the investment arm of Scotland’s national economic development agency, Scottish Enterprise. Its activities support Scotland’s SME funding market, making sure businesses with growth and export potential have adequate access to growth capital and loan funding.

Emily Henderson

Written by

Emily Henderson

During her time at AZoNetwork, Emily has interviewed over 300 leading experts in all areas of science and healthcare including the World Health Organization and the United Nations. She loves being at the forefront of exciting new research and sharing science stories with thought leaders all over the world.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Henderson, Emily. (2020, March 23). Biogelx announce Alison Clayton as new CEO. News-Medical. Retrieved on July 18, 2024 from https://www.news-medical.net/news/20200324/Biogelx-announce-Alison-Clayton-as-new-CEO.aspx.

  • MLA

    Henderson, Emily. "Biogelx announce Alison Clayton as new CEO". News-Medical. 18 July 2024. <https://www.news-medical.net/news/20200324/Biogelx-announce-Alison-Clayton-as-new-CEO.aspx>.

  • Chicago

    Henderson, Emily. "Biogelx announce Alison Clayton as new CEO". News-Medical. https://www.news-medical.net/news/20200324/Biogelx-announce-Alison-Clayton-as-new-CEO.aspx. (accessed July 18, 2024).

  • Harvard

    Henderson, Emily. 2020. Biogelx announce Alison Clayton as new CEO. News-Medical, viewed 18 July 2024, https://www.news-medical.net/news/20200324/Biogelx-announce-Alison-Clayton-as-new-CEO.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Swift transfer from pediatric to adult care may reduce the use of acute care services in sickle cell disease